1. New vaccine technology may be put to test with COVID-19 — FDA rejects Merck's 6-week Keytruda dosing schedule — Blood disorder startup Imara files for $86M IPO — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Glaucoma data

Discussion in 'Aerie Pharma' started by anonymous, Feb 16, 2019 at 6:10 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Mmm...looks too good. Who is the clininal lead ?
     

  2. anonymous

    anonymous Guest

    yes I wondered the same on the clinical results
     
  3. anonymous

    anonymous Guest

    Which trial/product are you talking about?
     
  4. anonymous

    anonymous Guest

    ROCK inhibitor
     
  5. anonymous

    anonymous Guest

    Yes you should check out TH from clinical...and the data analysed
     
  6. anonymous

    anonymous Guest

    No response ? Do you know what this thread means ?
     
  7. anonymous

    anonymous Guest

    The company can't afford to pay rebates. So its "covered" but is 150 freaken dollars. Data doesnt really matter. So who gives a shit?
     
  8. anonymous

    anonymous Guest

    the company CAN afford to pay rebates! It takes time. It’s unheard of for a new class to have the coverage that we have. Part D coverage after 4 months.... not one of our competitors can say that. So go spread your hate somewhere else. And you should probably be looking for a new job all of you Allergan and ALCON haters. There’s going to be a new gold standard coming! Keep trying to decrease the concentration and add more BAK to your products. It must be hard selling old products, your schemes of selling patents to Indians reservations just aren’t working, doctors know it! You time is numbered.
     
  9. anonymous

    anonymous Guest

    Stop being lured in by the trolls!

    The data, pfft, really?
    The damned drug's been on the market for about a year.
    Google it troll!
    (not the above poster, of course, the original poster/troller!)
     
  10. anonymous

    anonymous Guest

    We will keep adding BAK, and keep adding $$$$ to our bank accounts while doing it. You are helping us out immensely every time a patient quits your drug in disgust when they don't want to pay your ridiculous copays. It paves the way to go to another branded! Other companies have exceeded their goals due in part to your tireless work, of which you get paid close to nothing in commission. Thank you for growing the class and increasing awareness.
     
  11. anonymous

    anonymous Guest

    were growing your market share? That’s laughable. Is that why your market share is down? And you keep getting kicked off plans. Go ahead.... keep telling yourself you’re in a better position. True tear is a joke. Restasis multidose is on back order. And you no longer get credit for the vials. You are making HUGE bonus. #baller #allercant #lumigone #runingwithdrops aka your Indian tribe name.